Karyopharm and NeOnc announce upcoming financial and clinical updates

Karyopharm Therapeutics Inc. has announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. The company, which specializes in nuclear export inhibition for cancer therapies, will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide corporate updates.

Separately, NeOnc Technologies Holdings, Inc. has scheduled an investor conference call for Wednesday, August 12, 2026, to present topline results from the Phase 2a portion of its NEO100-01 clinical trial. The study evaluates the safety and efficacy of intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The company’s platform aims to address challenges regarding the blood-brain barrier, and its candidates currently hold FDA Fast-Track and Investigational New Drug status.